MedPath

Risk Prediction in Type II Diabetics With Ischemic Heart Disease

Conditions
Type-2 Diabetes Mellitus
Ischemic Heart Disease
Registration Number
NCT01422057
Lead Sponsor
Thebiosignals.com
Brief Summary

The purpose of this study is to test whether cardiac autonomic dysfunction predicts is a prognostic marker in type-2 diabetics with ischemic heart disease

Detailed Description

In patients with type 2-diabetes and ischemic heart disease autonomic function might be seriously affected.

In the present study, markers of cardiac autonomic dysfunction, repolarization and respiration abnormalities will be assessed from Holter recordings and 30-minute recordings of high-resolution three dimensional ECG, non-invasive arterial blood pressure and respiratory activity.

The correlation between markers of cardiac autonomic dysfunction and markers of severity of type-2 diabetes will be assessed. Autonomic dysfunction is assumed present when both heart rate turbulence and deceleration capacity are abnormal ("severe autonomic failure"). Assessment of severity of diabetes includes levels of HbA1c and urine albumine, duration and treatment of diabetes, and diabetes related complications (nephropathy, neuropathy, retinopathy).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
500
Inclusion Criteria
  • type-2 diabetes
  • coronary artery disease
Exclusion Criteria
  • age >80 years
  • acute coronary syndrome
  • life expectancy <1 year
  • unable to give informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Major cardiovascular event2 years

Combination of total mortality, non-fatal myocardial infarction and non-fatal stroke

Secondary Outcome Measures
NameTimeMethod
Cardiovascular mortality2 years
sudden cardiac death2 years
Total mortality2 years

Trial Locations

Locations (1)

Department of Cardiology

🇩🇪

Tübingen, Germany

© Copyright 2025. All Rights Reserved by MedPath